Physician profile
Danny Luong
NPI 1942524707
$3,976.69
in general payments reported to CMS, 2019-2025
23 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $58.54 · 2021: $76.34 · 2022: $221 · 2023: $729 · 2024: $807 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,983.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $884.92 | 2025 | Rapiblyk |
| Janssen Pharmaceuticals, INC | $385.58 | 2019-2023 | Xarelto |
| Csl Behring | $277.59 | 2019-2025 | Kcentra |
| E.R. Squibb & Sons, L.L.C. | $256.05 | 2019-2025 | Eliquis, Camzyos |
| Abbvie INC. | $253.92 | 2024-2025 | |
| Pfizer INC. | $252.17 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $234.92 | 2023-2025 | Rebyota |
| Shionogi INC | $203.91 | 2022-2025 | Fetroja |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.98 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $174.83 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Alexion Pharmaceuticals, INC. | $160.77 | 2023-2025 | Ultomiris |
| Cumberland Pharmaceuticals, INC. | $112.39 | 2019-2020 | |
| Insmed, INC. | $105.72 | 2023 | Arikayce |
| Novartis Pharmaceuticals Corporation | $105.26 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.00 | 2023-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $81.63 | 2022-2023 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $67.41 | 2019-2021 | |
| Astellas Pharma US INC | $56.11 | 2019 | |
| Aimmune Therapeutics, INC. | $25.02 | 2025 | Vowst |
| Eusa Pharma (US) LLC | $19.17 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.37 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.73 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.24 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Luong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.